Cancer Research UK Clinical Trials Unit

MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma

Abstract In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in tran...

A global study of novel agents in paediatric and adolescent relapsed and refractory B-cell non-Hodgkin lymphoma (Glo-BNHL): protocol for an adaptive international platform clinical trial

The second Paediatric Strategy Forum of the international multi-stakeholder organisation, ACCELERATE (Nov-2017), concluded that an international approach to conducting clinical trials in relapsed and refractory paediatric B-cell non-Hodgkin lymphoma (r/r B-NHL) was critical and t...

90 Developing Patient-Focused Outcomes for Routine Clinical Care in Glioma: A Synthesis of Qualitative Evidence from the COMBaT Study

Abstract Introduction There is a critical need to identify and routinely measure the outcomes that matter most to people living with glioma. Care needs in this population are complex and variable, yet current clinical practice lacks consistent, systematic approaches to assessing...

136 Tessa Jowell BRAIN MATRIX interim analysis: surgical and oncology outcomes in glioblastoma patients

Abstract Introduction The Tessa Jowell BRAIN MATRIX (TJBM) is a programme of work aimed at improving the knowledge of and treatment for glioma, comprising a platform study with subsequent interventional clinical trials. Methods Interim analysis of first 500 patients from 11 speci...

Strategic roadmap for delivery of clinical trials in rare childhood central nervous system (CNS) tumours: a multi-stakeholder consensus

Abstract Rare paediatric central nervous system (CNS) tumours comprise a biologically-heterogeneous group of low-incidence diseases that present significant challenges to both therapeutic development and clinical research, limiting the availability of high-quality evidence to gui...

Factors Associated With Progression From Level 1 to Level 2 Sensor‐Detected Hypoglycaemia in People With Type 1 and Insulin‐Treated Type 2 Diabetes: A Post Hoc Analysis From the Hypo‐ METRICS Study

ABSTRACT Aims We investigated the proportion of sensor‐detected hypoglycaemic (SDH) events progressing to level 2, and associated variables. Materials and Methods We used data from Hypo‐METRICS, which recruited people with type 1 (pwT1D) and insulin‐treated type 2 diabetes (pwT2D...